Transgene (Euronext Paris: TNG) has initiated a Phase 1 trial evaluating its Individualized Neoantigen Therapeutic Vaccine (INTV) candidate, TG4070, from its myvac platform, in combination with nivolumab, in the adjuvant treatment of resected non-small cell lung cancer (NSCLC).
According to Transgene, TG4070 is the second candidate from its myvac platform and leverages the company’s clinically validated Modified Vaccinia Ankara viral vector.
In a statement, Alessandro Riva, MD, chairman and CEO of Transgene, commented, “The initiation of this randomized Phase 1 trial of TG4070 represents an important step in Transgene’s strategy to expand the myvac platform beyond TG4050 in head and neck cancer, into additional early-stage solid tumor indications. The program reflects the growing integration of Transgene’s proprietary capabilities across AI-driven neoantigen selection through SNIPER and scalable manufacturing infrastructure designed to support broader platform deployment.”
